Shervin Assassi MD
Professor & Director, Division of Rheumatology, University of Texas Health Science Center at Houston
Join to View Full Profile
6431 Fannin StMsb 5.270Houston, TX 77030
Phone+1 713-500-6900
Fax+1 713-500-0580
Dr. Assassi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Rheumatology, 2003 - 2005- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2000 - 2003
Albert Ludwigs University Faculty of MedicineClass of 1999
Certifications & Licensure
TX State Medical License 2005 - 2025
American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Fellow (FACR) American College of Rheumatology
Publications & Presentations
PubMed
- Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles: Focus on Anti-Centromere and Anti-RNA Polymerase III Antibodies.Elizabeth R Volkmann, Shervin Assassi, Christopher P Denton, Rozeta Simonovska, Steven Sambevski
The Journal of Rheumatology. 2025-04-15 - Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.Yiming Luo, Shervin Assassi, Maureen D Mayes, Tracy M Frech, Virginia D Steen
Annals of the American Thoracic Society. 2025-04-10 - 1 citationsSerum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study.Monique Hinchcliff, Dinesh Khanna, Enrico De Lorenzis, Stefano Di Donato, Antonio Carriero
The Lancet. Rheumatology. 2025-03-31
Journal Articles
- The Scleroderma Patient-Centered Intervention Network Cohort: Baseline Clinical Features and Comparison with Other Large Scleroderma CohortsDaniel E Furst, Robert Spiera, Maureen D Mayes, Lorinda Chung, Suzanne Kafaja, Virginia Steen, Shervin Assassi, Monique Hinchcliff, Rheumatology
Press Mentions
Durable Efficacy for Drug Preventing Lung Progression in Systemic SclerosisJuly 20th, 2022- Higher Cardiovascular Risks in Kawasaki Disease Persist 10-plus YearsNovember 8th, 2020
Dr. Shervin Assassi: New Chair of the ACR Committee on Journal PublicationsApril 18th, 2019- Join now to see all
Grant Support
- Interferon Regulatory Factor 7 Links Interferon Pathway Activation to the Exaggerates Fibrotic Response in Systemic SclerosisUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON2023–2028
- Combined Optical Coherence Elastography and Tomography for Assessing Skin Involvement in Systemic SclerosisUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON2020–2025
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
